Retinitis Pigmentosa (RP) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Retinitis Pigmentosa (RP) Emerging Therapy and TPP Insights

Thelansis’s “Retinitis Pigmentosa (RP) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Retinitis Pigmentosa (RP) Overview

Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies marked by progressive photoreceptor degeneration, driven by mutations across more than 80 genes (including RHO, USH2A, and RPGR). It exhibits a peripheral-to-central degeneration pattern where rod dysfunction typically precedes cone involvement. Patients present with early night blindness, progressive visual field constriction producing tunnel vision, and late-stage central blindness. Diagnosis integrates fundoscopic examination revealing characteristic bone-spicule deposits, electroretinography showing blunted responses, and genetic testing to confirm variants. The AAV-based gene therapy voretigene neparvovec represents a landmark precision standard specifically for biallelic RPE65 mutations. For the vast non-RPE65 population, vitamin A palmitate provides modest, heavily debated slowing. In 2026, the advanced therapeutic paradigm has shifted toward gene-agnostic restoration. This is led by the optogenetic gene therapy MCO-010 (sonpiretigen isteparvovec), which uses an AAV2 vector to express multi-characteristic opsins in retinal bipolar cells. In early 2026, its rolling BLA was completed following three-year REMAIN trial extension data showing durable, significant visual acuity gains. Low vision aids complete the modern management model.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Retinitis Pigmentosa (RP) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026